Results 221 to 230 of about 177,994 (348)

Clinicopathological Characteristics of Lesions Diagnosed by MRI-Guided Biopsy in <i>BRCA1/2</i> Mutation Carriers. [PDF]

Eur J Breast Health
Nagata A, Tozaki M, Taruno K, Nakamura S, Hayashi N.   +4 more
europepmc   +1 more source

EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment [PDF]

, 2018
Miguel Martín, W. Eiermann, Hope S. Rugo, Johannes Ettl, Sara A. Hurvitz, Anthony Gonçalvès, Rinat Yerushalmi, Denka Markova, Iulia Cristina Tudor, JL Blum, A. Hannah, Jennifer K. Litton   +11 more
openalex   +1 more source

Clinical Significance of Biomarkers in Oropharyngeal Squamous Cell Carcinoma: Recurrence Prediction and Treatment Response

Cancer Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background Oropharyngeal squamous cell carcinoma (OPSCC) accounts for a substantial proportion of head and neck cancers, with a rising incidence largely driven by human papillomavirus (HPV) infection. Despite advances in multimodal treatment, disease recurrence remains common and limits long‐term survival, highlighting the need for reliable ...
Yunxia Chen, Wenyu Zhang, Xiang Gao, Kongling Xing, Yijing Ren, Jinyu Hu, Zhihao Xie, Ping Zhou   +7 more
wiley   +1 more source

RESPONSE: Re: Pretest Prediction of BRCA1 or BRCA2 Mutation by Risk Counselors and the Computer Model BRCAPRO [PDF]

, 2002
David Euhus
openalex   +1 more source

Antiproliferative Effects of Cannabinoids and Cisplatin in Cervical Cancer Cells

Cancer Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Introduction Cervical cancer remains a leading cause of cancer‐related mortality among women globally, particularly in low‐ and middle‐income countries. Cisplatin, a standard chemotherapeutic agent, is limited by severe toxicities and chemoresistance. This study aimed to assess the effects of cisplatin in combination with phytocannabinoids, Δ9‐
S. P. Mathibela, M. T. Lebelo, V. Steenkamp   +2 more
wiley   +1 more source

Ewing sarcoma fusion oncogene: At the crossroads of transcription and DNA damage response

Molecular & Cellular Oncology, 2018
Aparna Gorthi, Alexander J. R. Bishop
doaj   +1 more source

Resistance to neoadjuvant talazoparib in triple-negative breast cancer by BRN2-induced ATR/STAT3 pathways or SHLD2 subclone expansion. [PDF]

Proc Natl Acad Sci U S A
Abdulkareem NM, Jiang Y, Qi Y, Liu X, Zhang X, Cai S, Shao J, Jeter-Jones S, Rinkenbaugh AL, Cheng CC, Hancock F, Schwartz J, Litton JK, Chang JT, Piwnica-Worms H.   +14 more
europepmc   +1 more source

BRCA1/2遺伝学的検査陰性である乳がん女性のセルフ・トランセンデンス [PDF]

Sanae Aoki, Sawa FUJITA
openalex  

Targeting the nuclear export receptor exportin‐1 in acute myeloid leukaemia: From biology to clinical translation

Clinical and Translational Medicine, Volume 16, Issue 5, May 2026.
• XPO1 hyperactivation promotes leukaemogenesis by altering nucleocytoplasmic transport and transcriptional control in acute myeloid leukaemia (AML). • Selinexor and eltanexor show preferential activity in NPM1‐mutated, DEK::NUP214‐positive and SF3B1‐mutated myeloid neoplasms.
Yifan Liu, Xiaoya Yun, Weidong Ding, Suxiao Li, Hui Liu   +4 more
wiley   +1 more source

BRCA1/2 and CHEK2 Pathogenic Variants in Urological Cancers: A Portuguese Single-Center Experience. [PDF]

Cureus
Quinto Pereira M, Miguel I, Fragoso S, Duarte T, Santos S, Rodrigues P, Pereira C, Vaz F.   +7 more
europepmc   +1 more source